Disease · MONDO_0024290

enuresis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. enuresis. Diseases, record MONDO_0024290. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024290

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: enuresis; Open Targets
Open Targets ID: MONDO_0024290; Open Targets
MeSH: D004775; MeSH
NCI Thesaurus: C34588; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 8 drugs, from DailyMed and TTD; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DESMOPRESSIN ACETATE	CHEMBL1200556	Protein	Approval	DailyMed	3	0	0	Drugs and targets
IMIPRAMINE HYDROCHLORIDE	CHEMBL1692	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
VASOPRESSIN	CHEMBL373742	Protein	Approval	TTD	1	0	0	Drugs and targets
DESMOPRESSIN	CHEMBL1429	Protein	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
FLUOXETINE	CHEMBL41	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OXYBUTYNIN	CHEMBL1231	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROPIVERINE	CHEMBL1078261	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AVPR1A	Vasopressin receptor	3	Vasopressin receptor agonist	Approval	https://conductscience.org/library/genes/552	Drugs and targets
AVPR1B	Vasopressin receptor	3	Vasopressin receptor agonist	Approval	https://conductscience.org/library/genes/553	Drugs and targets
AVPR2	Vasopressin receptor	3	Vasopressin receptor agonist	Approval	https://conductscience.org/library/genes/554	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	2	Serotonin transporter inhibitor	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor M2	1	Muscarinic acetylcholine receptor M2 antagonist	Phase 3	https://conductscience.org/library/genes/1129	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	1	Muscarinic acetylcholine receptor M3 antagonist	Phase 3	https://conductscience.org/library/genes/1131	Drugs and targets
MTNR1A	Melatonin receptor	1	Melatonin receptor agonist	Phase 2	https://conductscience.org/library/genes/4543	Drugs and targets
MTNR1B	Melatonin receptor	1	Melatonin receptor agonist	Phase 2	https://conductscience.org/library/genes/4544	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	1	Norepinephrine transporter inhibitor	Approval	https://conductscience.org/library/genes/6530	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01078753	Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis	Phase 3	89	2011-11-02	Nocturnal Enuresis	DESMOPRESSIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00230594	Desmopressin Response in the Young	Phase 3	132		Primary Nocturnal Enuresis	DESMOPRESSIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04676139	The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children	Phase 3	100		Nocturnal Enuresis	FLUOXETINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT07028645	Uroflowmetry and Nocturnal Enuresis		100		Enuresis, Nocturnal	DESMOPRESSIN, PROPIVERINE	Its record names the disease	ClinicalTrials.gov
NCT02538302	Minirin Versus Oxybutynin for Nocturnal Enuresis in Children	Phase 3	66		Nocturnal Enuresis	DESMOPRESSIN, OXYBUTYNIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01575678	The Effect of Melatonin on Nocturnal Enuresis	Phase 2	40		Nocturnal Enuresis	MELATONIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02636387	Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease		14		Nocturnal Enuresis, Anemia, Sickle Cell	DESMOPRESSIN	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Desmopressin vs Placebo: serious adverse events	0 of 45	0 of 44	89	NCT01078753

Source Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30216627	RESULT	1	PubMed
28208214	RESULT	1	PubMed
20006865	RESULT	1	PubMed
40728007	DERIVED	1	PubMed
32364251	DERIVED	2	PubMed
27123229	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024290

GET https://conductscience.org/api/diseases/v1/MONDO_0024290/drugs

API reference For AI assistants